Google
DRUG — BRIGHT MINDS BIOSCIENCES INC (Healthcare >> Biotechnology)
DRUG FAQ
What is DRUG's ROE?
BRIGHT MINDS BIOSCIENCES INC reports a Return on Equity (ROE) of -8.93%.
What is DRUG's dividend yield?
BRIGHT MINDS BIOSCIENCES INC offers a dividend yield of 0.00%.
What is DRUG's Deepscope Quality Score?
Deepscope rates DRUG's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DRUG?
Deepscope's AI Timing Score for DRUG is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DRUG belong to?
BRIGHT MINDS BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 61.56
Price
-6.24
(-9.20%)
Day Change
|
|
|---|
DRUG, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 61.56 |
| PBV / Sector |
2.07 / 4.79
|
| Earning Per Share | -2.65 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
29.73 M
GREAT
|
| Average 1W Daily Value |
40.38 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:54:43 |
| Symbol | DRUG |
| Name | BRIGHT MINDS BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.81 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 639.45 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 19 Vestry Street, New York, NY, United States, 10013
Phone: 647 865 8622
Website: https://brightmindsbio.com
Sector: Healthcare >> Biotechnology
Description: Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
